GlassScriptPhysician profile
Travis W Zaplac
NPI 1932749892
$1,138.68
in general payments reported to CMS, 2019-2025
16 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $197 · 2022: $244 · 2023: $116 · 2024: $346 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $227.37 | 2021-2023 | Bexsero |
| Abbvie INC. | $124.40 | 2024 | |
| Corcept Therapeutics | $114.93 | 2024 | Korlym |
| Kerecis Limited | $105.44 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $96.87 | 2021-2022 | |
| Sanofi Pasteur INC. | $92.55 | 2021-2023 | |
| Nevro Corp. | $88.50 | 2024 | Senza |
| Inspire Medical Systems, INC. | $80.49 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $41.49 | 2021 | |
| Corium, LLC | $32.63 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $29.37 | 2025 | Gore Synecor Biomaterial |
| Alk-Abello, INC | $28.97 | 2021 | |
| Sobi, INC | $23.91 | 2023 | |
| Solventum Corporation | $20.42 | 2025 | Prevena, V.A.C.Ulta |
| Applied Medical Technology INC | $18.29 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Zaplac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.